Tag: casgevy

FDA Approves Vertex & CRISPR’s Gene Editing Therapy to treat Beta Thalassemia

Treat Beta Thalassemia

The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]

Read more


Secured By miniOrange